21:27 , Feb 22, 2019 |  BioCentury  |  Finance

Accessing Hong Kong

Leveraging its position in Hong Kong, the new CR-CP Life Science Fund aims to attract European and U.S. startups seeking growth opportunities in Hong Kong and China. The USD fund raised $150 million on Feb....
05:41 , Feb 8, 2019 |  BC Week In Review  |  Company News

China Resources, Charoen Pokphand launch $300M life science fund

China Resources Holdings Co. Ltd. (Hong Kong, China) and Thai conglomerate Charoen Pokphand Group (Bangkok, Thailand) launched the $300 million Hong Kong-based CR-CP Life Science Fund on Jan. 28. The general partners have committed $150...
23:38 , Feb 1, 2019 |  BC Extra  |  Financial News

China Resources, Charoen Pokphand launch $300M life science fund

China Resources Holdings Co. Ltd. (Hong Kong, China) and Thai conglomerate Charoen Pokphand Group (Bangkok, Thailand) launched the $300 million Hong Kong-based CR-CP Life Science Fund on Monday. The general partners have committed $150 million...
20:06 , Dec 19, 2018 |  BC Innovations  |  Translation in Brief

Taking the sting out of AMPs

Massachusetts Institute of Technology researchers led by Timothy Lu have developed a rational-design method for engineering antimicrobial peptides from toxic molecules such as wasp venom, publishing their third approach to developing AMPs this year and...
20:03 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Esherichia; Pseudomonas; Staphylococcus Mouse studies identified an analog of the wasp-derived peptide polybia-CP that could help treat E. coli , Pseudomonas and Staphylococcus infections. Chemical synthesis and screening in bacterial colony-based assays of polybia-CP...
19:55 , Jul 13, 2018 |  BC Week In Review  |  Company News

Aquinox halves workforce after sole clinical asset misses in Phase III

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) said in an SEC filing it reduced headcount by 30 (53%) and halted all development of sole clinical asset rosiptor (AQX-1125) after the compound missed in a Phase III trial last...
14:46 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Aquinox discontinues development of rosiptor

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) said its sole clinical asset, rosiptor (AQX-1125), missed the primary endpoint in the double-blind, international Phase III LEADERSHIP 301 trial to treat interstitial cystitis/bladder pain syndrome (IC/BPS). The company said it...
19:06 , Jun 27, 2018 |  BC Extra  |  Clinical News

Aquinox halts product development, stock nosedives

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) plummeted $12.97 (85%) to $2.34 Wednesday after sole clinical asset rosiptor (AQX-1125) missed the primary endpoint in the Phase III LEADERSHIP 301 trial to treat interstitial cystitis/bladder pain syndrome (IC/BPS). The...
18:32 , Aug 9, 2017 |  BC Innovations  |  Distillery Techniques

Drug properties

TECHNOLOGY: Physicochemical properties Formulations based on combinations of amino acids, sugars and emulsifiers could enable long-term, low-viscosity storage of high-concentration antibodies. Formulations of low (50 mg/mL), high (150 mg/mL) and ultra-high (175 mg/mL) concentrations of...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Company News

CPGJ, 3SBio deal

3SBio acquired a majority stake in biosimilar company Shanghai CP Guojian. 3SBio paid RMB1.4 billion ($219.1 million) to raise its stake to 54%. 3SBio had acquired a 7% stake in CP Guojian last year, according...